Petridis A, et al. - Experts evaluated the relationship of body mass index (BMI) and waist circumference (WC) on disease severity, to identify potential patient characteristics related to response attainment and to ascertain the effect of infliximab on the patients’ health-related quality of life (HRQoL) among infliximab-treated patients in the routine care setting of Greece. Findings suggested that disease activity was reduced and the quality of life of moderate-to-severe psoriasis patients improved with infliximab through 1 year of treatment, independent of their BMI and WC.